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Background: The impact of cardiovascular complications on health-related quality-of-life
(HRQoL) in type 2 diabetes mellitus has not been clearly established. Using EQ5D utility
data from SAVOR-TIMI 53, a large phase IV trial of saxagliptin versus placebo, we quantified
the impact of cardiovascular and other major events on HRQoL.
Methods: EQ5D utilities were recorded annually and following myocardial infarction (MI) or
stroke. Utilities among patients experiencing major cardiovascular events were analyzed
using linear mixed-effects regression, adjusting for baseline characteristics (including
EQ5D utility), and compared to those not experiencing major cardiovascular events. Mean
utility decrements with standard errors (SE) were estimated as the difference in utility
before and after the event.
Findings: The mean EQ5D utility of the sample was 0.776 at all time points, and did not dif-
fer by treatment. However, mean baseline and month 12 utilities among those with a major
cardiovascular event were 0.751 and 0.714. Mean utilities were 0.691 within 3 months of,
0.691 3–6 months after, and 0.714 6–12 months after, a major cardiovascular event. Cardio-
vascular event-specific utility decrements were 0.05 (0.007) for major cardiovascular events
over the same time periods. Decrements of 0.051 (0.012; myocardial infarction), 0.111 (0.022;
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 3 0 ( 2 0 1 7 ) 2 4 –3 3 25stroke), 0.065 (0.014; hospitalization for heart failure) 0.019 (0.024; hospitalization for hypo-
glycemia) were estimated; all coefficients were statistically significant.
Interpretation: Consistent with clinical outcomes reported elsewhere, saxagliptin did not
improve HRQoL. Cardiovascular complications were associated with significantly
decreased HRQoL, most substantial earlier after the event.
Funding: BMS/AZ.
 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes mellitus (T2DM) and its management can
have a dramatic impact on the health-related quality of life
(HRQoL) of those afflicted, in particular, among those who
develop microvascular and macrovascular complications [1–
4]. However, the exact HRQoL impact of macrovascular com-
plications, including major cardiovascular events, among
patients with T2DM has not been clearly established. Many
of the estimates of the impact of cardiovascular events on
HRQoL in T2DM come from cross-sectional studies [1–4];
which were not able to adequately consider the HRQoL
impact of pre-existing T2DM and its complications, how these
measures change over time, and the additive impact of mul-
tiple or recurrent cardiovascular events. The United Kingdom
Prospective Diabetes Study (UKPDS), for example, established
that while the occurrence of major cardiovascular events
could be shown to adversely impact HRQoL, intensive blood
glucose control did not improve it [3]. That study group also
reported utility [5] values for T2DM health states after major
cardiovascular events in T2DM based on a cross-sectional sur-
vey of patients as the trial drew to a close [6]. Although
macrovascular complications in T2DM are severe, they
remain relatively rare; robust measures from a large interna-
tional sample of patients with T2DM would be helpful to bet-
ter understand their HRQoL impact.
Saxagliptin (Onglyza, AstraZeneca and Bristol-Myers
Squibb) is a selective dipeptidyl peptidase 4 (DPP-4) inhibitor
that improves glycemic control compared to placebo [7]. The
Saxagliptin Assessment of Vascular Outcomes Recorded in
Patients with Diabetes Mellitus (SAVOR) – Thrombolysis in
Myocardial Infarction (TIMI) 53 multicentre randomized con-
trolled phase IV trial evaluated the safety and efficacy of sax-
agliptin with respect to cardiovascular outcomes in patients
with T2DM who are at risk for cardiovascular events.
Although DPP-4 inhibition with saxagliptin improved glyce-
mic control, it did not significantly increase or decrease the
rate of major cardiovascular events in the SAVOR-TIMI 53
trial, other than heart failure [8,9]. Given that almost 10% of
the SAVOR-TIMI 53 population experienced an ischemic car-
diovascular event over the follow up-period, and that
SAVOR-TIMI 53 was specifically powered to rigorously evalu-
ate their frequency, the SAVOR-TIMI 53 trial dataset repre-
sents a unique opportunity to further explore the burden of
cardiovascular events among those with T2DM. In the
SAVOR-TIMI 53 trial, the occurrence of composite endpoints
describing ischemic and overall cardiovascular events wasequivalent in the saxagliptin and placebo arms. However,
the proportion of patients hospitalized for heart failure was
statistically significantly higher in the saxagliptin arm (3.5%
vs. 2.8%; p = 0.007). While the proportion of those hospitalized
for hypoglycemia was numerically higher in the saxagliptin
arm, this difference was not statistically significant (0.6% vs.
0.5%; p = 0.33).
In addition to the clinical data collected with the SAVOR-
TIMI 53 trial, regular HRQoL data, in the form of the the
EuroQoL-5 dimension (EQ-5D) multi-attribute survey,[10] were
also collected. Assessments were conducted at baseline, dur-
ing routine assessments, and also following a major clinical
event. These longitudinal data from a large population of
patients may help to understand the impact of major cardio-
vascular events on HRQoL in T2DM, considering baseline
HRQoL status.
The objectives of this analysis were to describe the HRQoL
of the SAVOR-TIMI 53 trial population; compare mean utilities
over time according to treatment arm; quantify the impact of
major cardiovascular events on EQ5D utilities; and compare
utilities over time among those experiencing, and not experi-
encing, major cardiovascular events. As an exploratory objec-
tive, we also evaluated the impact of hospitalization for heart
failure or hypoglycemia on EQ-5D utilities.
2. Methods
2.1. SAVOR-TIMI 53 trial conduct
This is a secondary analysis of HRQoL data collected as part of
SAVOR-TIMI 53. SAVOR-TIMI 53 included 16,492 patients with
documented T2DM and either a history of previous cardiovas-
cular events or multiple risk factors for vascular disease,
enrolled from 788 sites worldwide and followed for a median
of 2.1 years, randomized 1:1 to saxagliptin or placebo. Both
patients who had prior treatment with glucose-loweringmed-
ication (with the exception of incretin-based therapy), and
treatment-naive patients, were enrolled. The full eligibility
criteria and further details of the study conduct have been
reported previously [8]. The primary efficacy and safety end-
point was a composite of cardiovascular death, nonfatal
myocardial infarction, or nonfatal ischemic stroke. The sec-
ondary efficacy endpoint included the primary composite
endpoint plus hospitalization for heart failure, coronary
revascularization, or unstable angina [8]. For the HRQoL anal-
yses reported here, the secondary endpoint from SAVOR-TIMI
53 was used, to incorporate any HRQoL impacts of hospital-
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event was also considered individually. Together, the events
comprising the secondary endpoint from SAVOR-TIMI 53 were
termed, ‘major cardiovascular events’. While not included in
the composite endpoint, hospitalized hypoglycemic events
are of clinical interest, and the HRQoL impact of these events
was also assessed by comparing HRQoL assessments before
and after such an event.
2.2. Health-related quality of life impact assessment
As part of the routine assessments within SAVOR-TIMI 53,
data from the EuroQOL-5 dimension (EQ-5D) survey were col-
lected. The EQ-5D survey measures HRQoL impacts for five
domains (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression) on three levels of 1 (no impact), 2
(moderate impact) and 3 (severe impact). Combinations of
responses to the domain questions result in 243 unique
health states to which respondents can be assigned; this
can be formally synthesized to a single utility value on a scale
of 0 (corresponding to being dead) to 1 (representing full
health). The EuroQol group’s UK-specific value set was used
to generate utility values based on the domain scores [11].
EQ-5D assessments were performed at baseline,
12 months, 24 months, and study completion; and at semi-
annual visits, among patients who had experienced non-
fatal myocardial infarction or ischaemic stroke since their
previous visit (Fig. 1). Although the SAVOR-TIMI 53 protocol
indicated EQ-5D administration linked to the incidence of
an event, there may have been up to six months’ lag time
between the event and the administration of the instrument.
For non-ischemic events and hypoglycemic events, additional
dedicated EQ-5D assessments were not performed, and sub-
sequent EQ-5D data were not available until the following
routine scheduled assessment.
In addition to and at the same time as the EQ-5D, all patients
also completed the EQ-5D visual analogue scale (VAS).Base-
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Fig. 1 – Schematic describing SAVOR protocol for EQ-5D data coll
primary composite endpoint: fatal CV event, non-fatal myocard2.3. Analysis
The baseline characteristics of the sample and the frequency
of EQ-5D data measurement were summarized. Continuous
variables were characterized by means and 95% confidence
intervals. Categorical variables were characterized by fre-
quency and percent distributions, and statistically compared
between groups using a chi-squared test. Categorical distribu-
tions of scores on individual EQ-5D domains were tabulated,
and EQ-5D utility values summarized; overall, at each individ-
ual visit, and following a major cardiovascular event. EQ-5D
utility datawere summarized both in terms of themean abso-
lute utility value specific to the health states of interest; but
also as utility decrements, or the difference in utility score
between health states, reflecting the incremental HRQoL
impact of major cardiovascular events on utility. Some indi-
viduals had multiple events, and utilities were all measured
relative to the most recent cardiovascular event.
Mixed effects regression models were fit, including
individual-level intercepts to account for the longitudinal
data structure in which individuals contributed multiple,
potentially correlated, observations. We fit an additive linear
mixed model, and explanatory variables included: treatment
arm, trial visit number, age, sex, baseline utility, and a time-
dependent variable for history of a cardiovascular event. A
covariate describing participant race was also considered,
but as the estimated coefficients were both statistically non-
significant and small in absolute value race was excluded
from the final models. EQ-5D measurements may have
occurred up to six months after a major cardiovascular event,
and up to one year after hospitalized hypoglycemic events,
such that, depending on the ongoing implications of the
event, its impact may be partially or fully missed by the
EQ-5D measure. To account for this, time between EQ-5D
measurement and cardiovascular event was included as a
categorical variable, stratified into categories of <3 months,
3–6 months, and 6–12 months.5 Close-out
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additional cardiovascular events on utility, a simple linear
regression model was fit describing utility measures elicited
following any cardiovascular event, with an exploratory vari-
able indicating the number of previous cardiovascular events.
2.4. Role of the funding source
This study was funded by AZ/BMS, and co-authors from
AZ/BMS participated in the in study activities as outlined in
the Contributors section. The corresponding author had full
access to all the data in the study and had final responsibility
for the decision to submit for publication.
3. Results
3.1. Description of the sample
Baseline clinical and demographic characteristics are pre-
sented by treatment arm in Table 1. In addition to the routine
EQ-5D measurements collected at baseline, 12 months,
24 months, and at the closeout visit, 594 additional measure-
ments were collected among 535 trial participants at the
semi-annual visit following a major cardiovascular event
(Table 1). In all, 1437 (8.7%) of the population met the inclu-
sion criteria of experiencing a major cardiovascular event
during SAVOR-TIMI 53 and having at least one subsequent
EQ-5D survey administered. The EQ-5D survey was adminis-
tered within 3 months of the event in 549 individuals (3.3%),
from 3 to 6 months from the event in 438 individuals (2.7%),
and within 6–12 months of the event in 741 individuals
(4.5%) (see Table 2).
In the primary SAVOR-TIMI 53 analysis, 2093 individuals
experienced the secondary composite cardiovascularTable 1 – Baseline clinical and demographic characteristics (n, %
Male sex
Age at diagnosis (mean, SD)
18–39 years
40–59 years
P60 years
Time since diagnosis (years median, interquartile range)
Baseline HbA1c
Major cardiovascular event during SAVOR and subsequent
EQ-5D measurement
Hospitalization for heart failure during SAVOR and subsequent
EQ-5D measurement
Hospitalization for hypoglycemia during SAVOR and subsequen
EQ-5D measurement
Myocardial infarction during SAVOR and subsequent EQ-5D me
Stroke during SAVOR and subsequent EQ-5D measurement
Timing of cardiovascular event compared to EQ5D elicitation*
<3 months
3 < 6 months
6 < 12 months
* Individuals experiencing more than one major cardiovascular event coendpoint. While the requirement imposed here of having an
EQ-5D survey administered following the event resulted in a
smaller number of events included, the distribution of events
between the saxagliptin and placebo treatment arms was
similar in both samples. Note that 656 individuals experi-
enced a major cardiovascular event but did not have a subse-
quent EQ-5D measurement, and 529 individuals died of
cardiovascular causes, suggesting that a majority of the
excluded individuals did not contribute EQ-5D results due to
cardiovascular death.
Hospitalization for heart failure occurred in 373 individu-
als with a subsequent EQ-5D result, while 79 individuals were
hospitalized with a hypoglycemic event and a subsequent
EQ-5D result.
3.2. EQ5D utility results
Mean utility values did not vary by treatment arm, and were
virtually unchanged over the time horizon of the SAVOR-
TIMI 53 trial. Mean EQ-5D utilities were 0.776 at baseline
and all subsequent time points; and the width of all confi-
dence intervals was within ±0.01 (Fig. 2). Therefore, there
was no evidence that saxagliptin was associated with a differ-
ence in HRQoL relative to placebo. Despite this lack of differ-
ence in utilities between the treatment arms, cardiovascular
events had a substantial impact on HRQoL and utilities.
Mean utility values at baseline are presented in Fig. 3,
stratified by whether an individual experienced a major car-
diovascular event by the end of the trial. The mean baseline
utility of 0.778 (95% CI: 0.775–0.783) was significantly higher
among those who never experienced a major cardiovascular
event compared to those who experienced a major cardiovas-
cular event during SAVOR-TIMI 53 (0.751 (0.739–0.763)). A
mean utility decrement of 0.050 (SE = 0.007) was observed).
Overall
(n = 16,488)
Saxagliptin
(n = 8279)
Placebo
(n = 8209)
11,034 (66.9) 5511 (66.6) 5523 (67.3)
1 (0.0) 1 (0.01) 0 (0.0)
4030 (24.4) 2031 (24.5) 1999 (24.4)
12,457 (75.6) 6247 (75.5) 6210 (75.6)
10.3 (5.3–16.7) 10.3 (5.3–16.7) 10.3 (5.3–16.6)
1437 (8.7) 731 (8.8) 706 (8.6)
373 (2.2) 214 (2.6) 159 (1.9)
t 79 (0.5) 45 (0.5) 34 (0.4)
asurement 415 (2.5) 205 (2.5) 210 (2.6)
208 (1.3) 112 (1.4) 96 (1.2)
549 (3.3) 282 (3.4) 267 (3.3)
438 (2.7) 219 (2.6) 219 (2.7)
741 (4.5) 386 (4.7) 355 (4.3)
uld appear in more than one time category.
Table 2 – Number of EQ-5D measurements recorded by visit in the SAVOR trial.
Overall Saxagliptin Placebo
Baseline 16,480 8,277 8,203
12 months 14,336 7,230 7,106
24 months 6,831 3,480 3,351
Closeout* 13,954 7,036 6,918
Following major cardiovascular event 1,437 731 706
Within 3 months of event 549 282 267
Within 3–6 months of event 438 219 219
Within 6–12 months of event 741 386 355
Additional elicitation outside of routine trial visits 535 253 282
* Mean time to closeout visit: 23.8 months.
n=8,277
n=8,203
n=7,230
n=7,106
n=3,480
n=3,351
Fig. 2 – Mean EQ-5D utility values over time, according to treatment arm, among the SAVOR trial population.
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a first major cardiovascular event. A utility decrement of 0.065
(SE = 0.014) was observed among individuals after hospital-
ization for heart failure (n = 373), compared to 0.051
(SE = 0.012) after myocardial infarction (n = 415) and 0.111
(SE = 0.022) after stroke (n = 208). A utility decrement of 0.019
(SE = 0.024) was observed following a hypoglycemic event
while hospitalized (n = 79).
For major cardiovascular events, the HRQoL and utility
impact was most substantial in the initial post-event period;
mean utility values among the subgroup of individuals expe-
riencing a major cardiovascular event, are presented in Fig. 4
by time since the event. Mean utility was observed to
decrease immediately after the event, and then gradually
increase, although it did not return to baseline by 12 months.
Further decreases were then observed at 24–30 months post-
event, which may reflect long-term clinical consequences of
the event, although relatively small sample sizes at this time
point, and corresponding wide variability, limits the interpre-
tation of observed trends. A clear temporal trend was not
observed for hospitalized hypoglycemic events (data notshown), although the sample size was notably smaller which
limited the power for analysis.
Results of the normal (identity link) generalized linear
mixed model are reported in Table 3, and coefficients illus-
trate the additive impact of each variable on utility values.
Increasing age was associated with a statistically significant
decrease, and male sex associated with a significant and
notable absolute increase of 0.033, in utility. After accounting
for individual-level trends via random effects, baseline HRQoL
was still associated with a statistically significant increase in
utility: a 0.1 increase on the utility scale was associated with
an estimated additive increase of 0.056. History of a cardio-
vascular event had a significant negative impact on utility,
with the magnitude of the impact increasing with proximity
to the event. On the additive scale, the decrease in utility
ranged from 0.035 for events occurring 6–12 months prior to
EQ-5D elicitation, to 0.057 for events occurring within
3 months prior to EQ-5D elicitation.
The impact of major cardiovascular events on utility
values waned with greater time since the event. After a car-
diovascular event, mean utilities were 0.691, 0.691, and 0.714
n=2,095
n=14,385M
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Fig. 3 – Mean baseline EQ-5D utility values and 95%
confidence interval, according to CVevent status, among the
SAVOR trial population.
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event, respectively). Predicted utility values were similar
between saxagliptin and placebo (data not shown). Utilities
were similar across trial visits, and the only notable differ-
ence was a trend towards lower utilities on follow-up mea-
surements, which is expected as such measurements were
triggered by major clinical events.Fig. 4 – Mean (±95% confidence interval) EQ-5D utility values ove
the SAVOR trial population who experienced a major cardiovas3.3. EQ5D utilities and domain scores following a
cardiovascular event
The distributions of EQ-5D domain at baseline and closeout in
the overall SAVOR-TIMI 53 population, and at baseline and
following a major cardiovascular event in those that experi-
enced them, are presented in Table 4. Among those who ever
experienced a major cardiovascular event during the trial,
EQ5D domain distributions were less favorable at baseline
compared to the overall population, particularly for the
mobility, pain/discomfort, and usual activities domains.
Domain scores dropped even further after experiencing a
major cardiovascular event. For the mobility domain, among
those who ever experienced a cardiovascular event during
the trial, the proportion reporting at least a moderate impact
increased from 49.5% at baseline, to 54.4% following a cardio-
vascular event, comparedwith 42.1% of the overall population
at baseline.
In the exploratory regression analysis of utility following
subsequent major cardiovascular events, the intercept was
0.753 (p < 0.001), with a coefficient for number of cardiovascu-
lar events of 0.038 (p < 0.001), indicating an additional utility
decrement of 0.038 for each additional event experienced.
The findings from the analyses of the EQ-5DVAS data were
consistent with those of the EQ-5D for all outcomes assessed.
In addition to the linear regression model presented here,
a gamma generalized linear model for utilities, in which
covariates were modeled to have a multiplicative rather than
additive effect, was also considered and fit to the data. For
clarity, only the linear model results are presented here, as
results were generally consistent across the two models,
and diagnostics indicated a better fit for the linear model.r time since a cardiovascular event, among the subgroup of
cular event.
Table 3 – Mixed effects linear regression results of EQ-5D converted utility values at all recorded visits in the SAVOR trial (UK
tariffs)*, n = 16,457 individuals included.
Variable Estimated coefficient
(additive on utility scale)
Standard error p-Value
Intercept 0.375 0.012 <0.001
Visit
12 month (reference) 0 NA NA
24 month 0.009 0.002 <0.001
Closeout 0.005 0.002 0.008
Additional elicitation following cardiovascular event 0.023 0.008 0.003
Treatment arm
Placebo (reference) 0 NA NA
Saxagliptin 0.006 0.003 0.129
Age (years) 0.001 0.000 <0.001
Sex
Female (reference) 0 NA NA
Male 0.033 0.003 <0.001
Baseline utility 0.560 0 <0.001
History of cardiovascular event
None (reference) 0 NA NA
<3 months 0.057 0.008 <0.001
3 < 6 months 0.043 0.009 <0.001
6 < 12 months 0.035 0.007 <0.001
History of on-trial hypoglycemic event
No history (reference) 0 NA NA
History 0.027 0.020 0.157
* UK-specific value sets for health states were applied to EQ-5D results in order to derive utility values relevant to a UK population.
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linear model does statistically allow for utility predictions
greater than 1.0, given the distribution of the data and vari-
ability, this was not a practical concern.
4. Discussion
Macrovascular complications, including the development of
cardiovascular disease, are a major source of burden for indi-
viduals with T2DM [12]. However, the exact magnitude of this
burden has not been established, particularly with respect to
patient-reported outcomes such as HRQoL. The SAVOR-TIMI
53 trial provided a unique opportunity to examine the
relationship between cardiovascular events and HRQoL in
individuals with T2DM, given its large sample size and con-
siderable follow-up period, and that the trial was powered
to rigorously evaluate the frequency of cardiovascular events
in a T2DM population [8,13]. The SAVOR-TIMI 53 trial protocol
included measurement of EQ-5D data from participants at
baseline, throughout study follow-up, and within
6–12 months following cardiovascular events. As a result, suf-
ficient data were available to compare HRQoL outcomes in
individuals who did and did not experience cardiovascular
events, and over time to assess the temporal impact of an
event on subsequent HRQoL.
While consistent with SAVOR-TIMI 53 trial results reported
elsewhere for clinical events [13], that saxagliptin did not
significantly improve HRQoL, cardiovascular events were
associated with a significant decrease in HRQoL that wasmost substantial in the initial post-event period. After adjust-
ing for age, sex, treatment arm, and baseline HRQoL, utility
decrements associated with cardiovascular events were
0.059 within 3 months of the event, 0.045 3–6 months after
the event, and 0.037 6–12 months after the event; the statisti-
cally significant reductions in health state utility observed ini-
tially following a cardiovascular event dampened over time.
These findings highlight the need to elicit utilities proximal
to the occurrence of the events of interest, in order to accu-
rately and comprehensively quantify the HRQoL burden.
Applying these utility decrements for 12 months after the
event, results in an estimated reduction of approximately half
a month of quality-adjusted life. When this total decrement
in quality-adjusted life years is applied to the difference in
major cardiovascular event rates across treatment arms
(8.8% vs. 8.6%), the treatment effect per individual is esti-
mated to be 0.000089 quality-adjusted life years, consistent
with the finding reported here of no significant association
between treatment and HRQoL.
These analyses also demonstrated that individuals who
experience cardiovascular events have poorer baseline func-
tion and HRQoL, compared to those who did not experience
cardiovascular events. This is consistent with other studies,
in which similar trends have been noted[6]. The less favorable
EQ5D scores (particular for mobility, pain/discomfort and
usual activities) and lower mean baseline EQ5D utilities
document HRQoL impairments prior to the occurrence of
the index event, and highlight the importance of adjusting
utilities for baseline health status. The analyses conducted
Table 4 – The n (%) of SAVOR subjects reporting each EQ-5D domain score at baseline and closeout; and at baseline and after a
major event, among the subgroup of SAVOR subjects experiencing cardiovascular events (n = 2568 post-event measures in
1437 individuals – note that 1424 have measures at baseline).
Overall population (N = 16,488*) Those experiencing cardiovascular events (N = 2,568)
Baseline Overall Baseline After cardiovascular event
Domain Level n % n % n % n %
Mobility 1 9,460 57.9 8,053 59.4 719 50.5 1,171 45.6
2 6,838 41.9 5,432 40 703 49.4 1,369 53.3
3 40 0.2 83 0.6 2 0.1 28 1.1
Self-care 1 14,711 90 12,003 88.5 1,269 89.1 2,111 82.2
2 1,524 9.3 1,429 10.5 146 10.3 409 15.9
3 102 0.6 131 1 9 0.6 48 1.9
Usual activities 1 11,852 72.5 9,826 72.4 965 67.8 1,509 58.8
2 4,191 25.7 3,424 25.2 428 30.1 913 35.6
3 295 1.8 316 2.3 31 2.2 145 5.6
Pain/discomfort 1 7,727 47.3 6,729 49.6 604 42.4 1,036 40.3
2 7,979 48.8 6,270 46.2 758 53.2 1,362 53
3 631 3.9 568 4.2 62 4.4 171 6.7
Emotional 1 11,436 70 9,825 72.4 988 69.4 1,675 65.2
2 4,586 28.1 3,491 25.7 407 28.6 822 32
3 313 1.9 248 1.8 29 2.0 72 2.8
* Of 16,488 individuals providing any EQ-5D visit, not all individuals provided valid measures for all domains at all visits. For each individual
domain and time point, the denominator for calculating percentages is taken to be the total number with a valid measurement for that domain
at that time point).
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ciated with hypoglycemic events in individuals with T2DM,
although the study was not specifically powered to study this
population. Further investigating this association would be
best addressed by a study designed to include a sufficient
number of hypoglycemic events.
HRQoL findings for cardiovascular events in T2DM from
SAVOR-TIMI 53 are generally consistent with those reported
in other studies (below) of HRQoL impacts due to macrovascu-
lar complications in individuals with T2DM. The United
Kingdom Prospective Diabetes Study (UKPDS) included more
than 5000 newly-diagnosed diabetic patients[6]; because the
population was not specifically recruited with respect to car-
diovascular risk, relatively few events were observed. In the
UKPDS, the observed HRQoL impact of cardiovascular events
was greater than that observed for SAVOR-TIMI 53, although
variability was substantial due to relatively small sample
sizes, and the estimates observed in the present analyses
were within the range of sampling error. While follow up in
the UKPDS was longer (mean follow up time, ten years),
SAVOR-TIMI 53 reflects a more contemporary and multina-
tional population than that of the UKPDS, who were recruited
between 1977 and 1991 only from the UK. Findings from the
present study were consistent with those from three other
smaller studies looking at utility decrements following car-
diovascular events in diabetes, including another study con-
ducted in 2048 individuals with type 1 or 2 diabetes mellitus
and T2DM, which also reported a utility decrement of 0.058
associated with cardiovascular disease [1,2,4]. Within the
temporal analyses conducted here, we considered the HRQoL
impact by time since event occurrence, and found that
impacts on utility were dampened over time. Nonetheless,HRQoL does not tend to return to pre-event levels within
one year of the event. We also considered baseline utility for
the subgroup of individuals who experienced a cardiovascular
event and found it to be significantly lower than the popula-
tion average, potentially due to ill health experienced in the
time prior to the event. This was adjusted for in the statistical
modeling to assess the utility impact of the event itself, inde-
pendent of underlying health status.
The key strength of this study was the rich data source
available, specifically, a large study of over 16,000 individuals
with extensive follow-up data available. Based on trial inclu-
sion criteria specifying a high cardiovascular risk patient pop-
ulation, this resulted in more than 2500 longitudinal utility
elicitations conducted in more than 1400 individuals experi-
encing a cardiovascular event. The longitudinal nature of
the data allowed for characterization of the changing HRQoL
impact of a cardiovascular event over time. The collection of
baseline utility data allowed for model adjustment by base-
line HRQoL status, reflecting the fact that individuals who
go on to experience cardiovascular events may have poorer
HRQoL in advance of event occurrence related to increased
risk factors, and allowing for this to be formally accounted
for in the analysis.
Limitations to the study included that, for approximately
half of all individuals experiencing a cardiovascular event,
the most proximal subsequent utility measurement was
6–12 months following the event. However, more than 500
individuals contributed EQ-5D values within three months
of an event, allowing for meaningful assessment of the initial
impact of the event on HRQoL. The EQ-5D is a generic HRQoL
instrument and while very useful for estimating utility values
and allowing standardized comparisons across disease states,
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While UK-specific tariffs were used to estimate EQ-5D utilities
from the raw data, SAVOR-TIMI 53 was a multinational study
with patients recruited at sites worldwide. Using other
country-specific tariffs could therefore yield slightly different
parameter estimates. Finally, there is the potential for mis-
classification of outcomes, based on timing of utility elicita-
tions, and this potential bias could impact the results in
either direction. Underestimation of utility decrements could
occur if a true utility decrement both occurred and resolved
between elicitations, such that it is never captured; while
overestimation could occur if the utility elicitation occurred
very shortly after the event, and the captured utility decre-
ment is assumed until the following visit. In addition,
detailed clinical data were not available to characterize the
severity of cardiovascular events, so this level of clinical detail
was not incorporated into the analysis.
Although these analyses of data from the SAVOR-TIMI 53
trial did not find that saxagliptin improved HRQoL, experienc-
ing cardiovascular events was associated with a significant
decrease in HRQoL most substantial in the initial post-event
period. These data also suggest a potential relationship
between hypoglycemic events and HRQoL; investigating this
association would be best addressed by a study designed to
include a sufficient number of hypoglycemic events.
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